ovarian cancer

[International Journal of Molecular Sciences] Investigators summarize current evidence-based knowledge on the cancer stem cell niche within the ovarian cancer tumour microenvironment and its effect on immune surveillance.

[Journal of Cellular and Molecular Medicine] Investigators identified that both ectopic wild type and nonISGylatable mutant interferon‐stimulated gene 15 (ISG15) expression inhibited CSC‐like phenotypes of cisplatin‐resistant ovarian cancer cells.

[Cell Death & Disease] Loss of PTEN in fallopian tube epithelium led to the enrichment of CSC markers such as LGR5, WNT4, ALDH1, CD44.

[Journal of Experimental & Clinical Cancer Research] Scientists discuss recent studies that have characterized the translational potential of patient’s derived organoids to inform on drug sensitivity of high grade serous ovarian cancer patients.

[Stem Cell Research] The authors generated two iPSC lines ZNHi001-A and ZNHi001-B from a prostate cancer patient carrying germline mutation in CHEK2 which might increase the risk of prostate cancer. Pluripotency and multi-lineage differentiation capacity of the two iPSC lines were confirmed by gene expression and teratoma assay.

[Anixa Biosciences, Inc.] Anixa Biosciences, Inc. announced that an IND (Investigational New Drug) application for its ovarian cancer CAR-T therapy has been filed with the FDA.